IVim Technology

IVim Technology OCF Margin

The Operating Cash Flow Margin of IVim Technology (460470.KQ) as of Nov 3, 2026 is -97.05 %. In the previous year, Operating Cash Flow Margin was -194.44 % — a change of -50.09% (higher).

OCF Margin

-97.05 %

YoY

-50.09%

Last updated:

Operating Cash Flow Margin of IVim Technology is 2025 -97.05 % . Operating Cash Flow Margin of IVim Technology was 2024 -194.44 % . It decreases by -50.09% higher compared to the previous year.

The IVim Technology OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2021
-670.01 KRW
Jan 1, 2022
-305.16 KRW
Jan 1, 2023
-76.67 KRW
Jan 1, 2024
-194.44 KRW
Jan 1, 2025
-97.05 KRW
The IVim Technology OCF Margin history
YEAROCF MarginYoY
-97.05 %-50.09%
-194.44 %+153.62%
-76.67 %-74.88%
-305.16 %-54.45%
-670.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVim Technology Stock analysis

What does IVim Technology do? IVim Technology Inc generates revenue through the development, manufacture, and sale of biological microscopes utilizing in vivo live cell imaging platform technology. The company offers imaging accessories and provides cellular-level imaging acquisition services inside living bodies along with kinetic analysis services for injected drugs. Its primary customers are healthcare institutions requiring advanced imaging solutions for research and diagnostic purposes. The firm targets the health care equipment and supplies industry segment focused on in vivo cellular analysis and drug development support. The company's core products include biological microscopes capable of analyzing complex dynamic changes in numerous cells in vivo, imaging accessories, and specialized services for cellular imaging and drug kinetics. These offerings are tailored to meet the needs of medical research facilities and pharmaceutical companies seeking to enhance their in vivo analysis capabilities. IVim Technology Inc's business model centers on providing integrated solutions for cellular-level imaging and drug efficacy assessment within the healthcare sector. Revenue streams are derived from direct sales of microscopes and accessories to healthcare providers and research institutions. The company also monetizes its expertise through service-based contracts for cellular imaging acquisition and kinetic drug analysis. These services are particularly valuable for pharmaceutical firms conducting preclinical studies and developing new treatments. The firm's focus on in vivo live cell imaging technology positions it as a key supplier for advanced medical research applications. IVim Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVim Technology stock

Operating Cash Flow Margin of IVim Technology is -97.05 % in 2025.

Operating Cash Flow Margin of IVim Technology changed from -194.44 % to -97.05 %, representing a -50.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin IVim Technology since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's IVim Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — IVim Technology

All Key Metrics — IVim Technology